In lung cancer, the presence of FSP1 maintains the growth of lung cancer cells when GPX4 is inactivated, so an apparent targeting of FSP1 seems to be a new target for cancer therapy, the study said (169, 170). The gene discussed is GPX4; the disease is lung carcinoma.